The presence of KRAS mutations is often associated with aggressive tumor phenotypes and resistance to therapy (Bahrami et al. 2018; Ng et al. 2013), which underlines the urgent need for models that can accurately replicate these mutations for research and therapeutic development. Here, KRAS is linked to neoplasm.